- Home
- FCFS vs GRFS Comparison
FCFS vs GRFS Comparison
Compare FCFS & GRFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FCFS
- GRFS
- Stock Information
- Founded
- FCFS 1988
- GRFS 1940
- Country
- FCFS United States
- GRFS Spain
- Employees
- FCFS N/A
- GRFS N/A
- Industry
- FCFS Other Specialty Stores
- GRFS Biotechnology: Pharmaceutical Preparations
- Sector
- FCFS Consumer Discretionary
- GRFS Health Care
- Exchange
- FCFS Nasdaq
- GRFS Nasdaq
- Market Cap
- FCFS 6.0B
- GRFS 6.2B
- IPO Year
- FCFS 1991
- GRFS 2006
- Fundamental
- Price
- FCFS $122.45
- GRFS $10.10
- Analyst Decision
- FCFS Strong Buy
- GRFS Hold
- Analyst Count
- FCFS 2
- GRFS 1
- Target Price
- FCFS $133.50
- GRFS $10.30
- AVG Volume (30 Days)
- FCFS 273.8K
- GRFS 1.1M
- Earning Date
- FCFS 07-24-2025
- GRFS 01-01-0001
- Dividend Yield
- FCFS 1.38%
- GRFS N/A
- EPS Growth
- FCFS 24.45
- GRFS N/A
- EPS
- FCFS 6.50
- GRFS 0.31
- Revenue
- FCFS $3,388,177,000.00
- GRFS $7,968,532,207.00
- Revenue This Year
- FCFS $3.76
- GRFS $7.14
- Revenue Next Year
- FCFS $6.68
- GRFS $7.16
- P/E Ratio
- FCFS $18.77
- GRFS $41.40
- Revenue Growth
- FCFS 2.49
- GRFS 10.76
- 52 Week Low
- FCFS $100.24
- GRFS $6.19
- 52 Week High
- FCFS $138.42
- GRFS $10.30
- Technical
- Relative Strength Index (RSI)
- FCFS 30.91
- GRFS 67.23
- Support Level
- FCFS $129.28
- GRFS $9.66
- Resistance Level
- FCFS $135.99
- GRFS $10.30
- Average True Range (ATR)
- FCFS 3.53
- GRFS 0.26
- MACD
- FCFS -1.21
- GRFS 0.00
- Stochastic Oscillator
- FCFS 12.08
- GRFS 85.19
About FCFS FirstCash Holdings Inc.
FirstCash Holdings Inc operates pawn stores in the United States and Latin America. Its primary business involves making small loans secured by personal property. The the company has three reportable segments: U.S. pawn; Latin America pawn; and Retail POS payment solutions (AFF). It derives majority revenue from U.S. Pawn segment. These pawn loans give the borrower the option of either repaying the loans with interest or forfeiting the property without further penalty. Geographically operates in USA, Mexico, Latin America, with maximum revenue from USA.
About GRFS Grifols S.A.
Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.